Targeting CaSR in the parathyroid gland by the FDA-approved drug cinacalcet or other calcimimetics suppresses parathyroid hormone (PTH) secretion, which is commonly used to treat secondary hyperparathyroidism associated with chronic kidney disease or renal failure. This evidence concerns the gene PTH and kidney failure.